Emeren : Corporate Presentation May 2024 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Novavax (NVAX) stock as Shah Capital withdraws its proxy campaign against the company following a licensing agreement with Sanofi (SNY). Read more here.
Hedge fund Shah Capital will end its proxy campaign against the re-election of three broad directors at Covid-19 vaccine maker Novavax after the company signed a licensing deal with French drugmaker Sanofi, according to a report by Reuters.
Hedge fund Shah Capital said on
Monday that it was withdrawing its preliminary proxy statement
and its campaign against the re-election of three directors on
Novavax s board. Shah.
Hedge fund Shah Capital said on
Monday that it was withdrawing its campaign against the
re-election of three directors on Novavax s board, days
after the COVID-19 vaccine maker struck a licensing deal.